IntroductionNon-coding RNAs are become one of the most investigated biomarkers in non-invasive diagnostics of cancer diseases. In this study we explore the potential of three miRNAs and one lncRNA as biomarkers in advanced laryngeal cancer (LSCC).Material and methodsPlasma samples were obtained from 22 patients with advanced LSCC and 21 healthy controls. Relative expression of miR-145–5 p, miR-196a-5p, miR-222–3 p and lncRNA MALAT1 was performed with RT-qPCR. Data was analysed by SPSS 17.0. A p-value less than 0.05 was considered statistically significant.Results and discussionsOur data showed significant ectopic expressions of miR-145–5 p (p=0.022), miR-222–3 p (p=0.013), miR-196a-5p (p=0.055), and lncRNA MALAT1 (p=0.004) in LSCC patients. Decreased expression levels of miR-145–5 p were obtained in 16 patients (mean RQ=0.828;SD=1.42,n=22), miR-222–3 p in 13 patients (mean RQ=0.59;SD=0.88;n=22) and lncRNA MALAT1 in 9 patients (mean RQ=0.67;SD=0.42;n=22). Upregulated levels of miR-196a-5p were reach in 17 patients (mean RQ=2.99;SD=1.43;n=22). Association analysis between markers and TNM stage, differentiation, tumour localization, tobacco and alcohol use was performed. Significant relation between lncRNA MALAT1 with nodal metastasis (p=0.049) and differentiation stage (p=0.020) were reached, as highest expression levels were obtained in those patients with nodal metastasis and poor differentiation tumour. None of the miRNAs showed significant association with any of clinicopathological characteristics. In order to evaluate the potential of included in the study markers as discriminative markers for LCSS patients, we used ROC analysis. The strongest significant potential was combination of miR-145–5 p, miR-196a-5p and lncRNa MALAT1 with AUC=0.870 (p=0.0001,95%CI:0.758–0.982; 86.4% sensitivity and 71.4% specificity). Separately, the ROC results showed for miR-222–3 p: AUC=0.703 (p=0.022,95%CI:0.547–0.860), miR-145–5 p: AUC=721(p=0.013 95% CI:0.570–0.872), miR-196a-5p: AUC=0.671 (p=0.055, 95% CI:0.4860.856), and lncRNA MALAT1: AUC=0.753 (p=0.004, 95% CI: 0.601–0.905).ConclusionOverexpression of included in the study miRNAs and lncRNA might take role in cancerogenesis of LSCC. In addition, lncRNA MALAT was associated with advanced tumorogenesis. The fusion of miR-145–5 p, miR-196a-5p and MALAT1 could be potential marker for non invasive diagnostic of LSCC. Grants:This work was supported by Project№ 8553/12.12.2016/Contract №D-137/MU-Sofia; DUNK01/2/2009/NSF.
IntroductionProtein arginine methyltransferases (PRMTs) are composed of nine family members that catalyse the methylation of the guanidine group of arginine residues. PRMT1, the main asymmetric dimethyltransferase, is responsible for 85% of all cellular arginine methylation, and has been increasingly associated with cancer pathogenesis. This is particularly true within the breast: PRMT1 levels are increased in breast cancer compare to the normal mammary gland and its expression correlates with poor patient survival. Proteomic approaches were used to identify novel PRMT1 substrates, enabling a better understanding into how PRMT1 promotes malignant progression.Material and methodsTAP-tag purification and mass spectrometry has identified the deubiquitinating enzyme (DUB) USP11 as a novel substrate of PRMT1. Methyl acceptor site was established by mass spectrometry and in vivo and in vitro methylation assays were performed to confirm PRMT1-mediated methylation. Generation of USP11 knockdown MCF7 cells reconstituted with wild type or methyl-deficient USP11 were used to probe biological significance.Results and discussionsWe confirmed that USP11 is a PRMT1 interacting protein by co-immunoprecipitation, but more importantly demonstrated that USP11 is a substrate of PRMT1 using recombinant hUSP11 and [3H]-S-adenosyl methionine in an in vitro methylation assay. Critically, methylation of USP11 in MCF7 cells, was reduced upon PRMT1 depletion. We identified R433 as the main PRMT1-mediated methylated arginine residue of USP11. R433 is located in the catalytic core domain of USP11, a residue that is conserved in different species and in its paralogues, USP4 and USP15. USP11 is a known regulator of the DNA damage response. Interestingly, methyl-deficient USP11-R433K showed a reduction in its catalytic activity in vitro whilst expression of USP11-R433K resulted in 53 BP1 retention and in a decrease in RAD51 foci formation, indicative of defective homologous recombination-mediated double strand break repair. Finally, we observed a crosstalk between arginine methylation and ubiquitination because overexpression of USP11 promotes the deubiquitination of PRMT1.ConclusionOur studies identify for the first time that DUBs are modified by arginine methylation, and that this post-translational modification has the potential to control the enzymatic activity of DUBs involved in double strand break repair. Understanding how methylation of USP11 contributes to genome stability will be important for understanding drug resistance in breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.